Galectin Therapeutics Inc. (GALT)

[biotech2010]

If you watched the presentation yesterday the answer would undoubtedly be a resounding 'NO'.

He said 'there had been lots of discussions' to a question that wasn't audible that was probably about partnerships.

Shlevin was also asked a question that wasn't audible on the webcast but his answer was clearly 'they are waiting for clinical data', the next round of which is in December. That could have been a question about partnerships as well.

Everyone needs make up their own minds about investments but I found GALT's presentation, like all of the prior ones, to be really weak-they barely touched on the Portland cancer trial, spent less than 2 minutes on psoriasis and atopic dermatitis, and, as always, spent most of the presentation speaking about animal trials and the role of Galectin 3 in these diseases. Again, speaking only for me I watched both CNAT and GALT back to back and moved money from CNAT to GALT as the result and now have 90% of my biotech asset allocation in CNAT and 10% in GALT; prior to September 27th it was 100% GALT